Anna Wagner, MD, University of Lausanne, Lausanne, Switzerland, provides an overview of the Phase II INNOVATION trial (NCT02205047) of neoadjuvant chemotherapy and trastuzumab with or without pertuzumab in patients with HER2+ gastric cancer. Patients were randomized to receive chemotherapy alone, chemotherapy with trastuzumab, or chemotherapy with trastuzumab and pertuzumab. Chemotherapy either consisted of cisplatin and fluorouracil, or FLOT as per the FLOT4 trial (NCT01216644). Patients receiving FLOT with trastuzumab had the highest median pathologic response. Despite the benefits of liquid biopsies, they were not conducted in this trial due to patient recruitment difficulties. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть